Media Articles

ICON announced its financial guidance for the year ended December 31, 2019, featuring commentary from Steve Cutler.

An all-encompassing digital era has opened unique opportunities for industry to engage with patients meaningfully. Read more in PharmaTimes' Jan. 2019 article.

ICON’s Marie McCarthy, Pavel Lebesle, and Matthew McCarty discuss how to accelerate drug development for patients with rare diseases in this Pharmafile article.

Read this MPO Magazine article written by ICON expert Vicki Anastasi on how value-based healthcare (VBHC) models are expected to transform the health sector.

Read this article to learn how to improve the efficiency of trial designs & procedures throughout the drug development process.

Discover the top digital & tech developments in the life science industry, including mHealth, AI, robotic process automation, and more.

Discover the importance of specialist epidemiology knowledge, due to their specialised focus on pharmacoepidemiological study design, to ensure robust and reliable downstream study findings.

An article written by Kerina Bonar & Rob Sambrook, exploring opportunities for pairing hybrid study design with epidemiological expertise for RWE generation.

E.B. McLindon explains how ICON is taking a different approach with its Integrated Site Network in this Scrip 100 media article.

The cost challenges presented by precision medicine in rare disease, and the strategies that can be employed to overcome them.